VYNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vyne Therapeutics Inc (VYNE) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish momentum, the lack of positive news, weak financial performance, and bearish short-term stock trend suggest caution. With no significant catalysts or trading signals, it is better to hold off on investing in this stock for now.
The MACD is slightly positive and expanding, indicating mild bullish momentum. The RSI is neutral at 64.621, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 0.622 and 0.636, while support levels are at 0.577 and 0.563.
Revenue increased by 54.76% YoY in Q4 2025, and gross margin remained strong at 100%.
Net income dropped significantly by -59.77% YoY, and EPS declined by -60.71% YoY. No recent news or significant trading trends from hedge funds or insiders. Stock trend analysis predicts a decline of -1.41% in the next day, -5.34% in the next week, and -7.29% in the next month.
In Q4 2025, revenue grew to $130,000 (+54.76% YoY), but net income dropped to -$4,837,000 (-59.77% YoY), and EPS fell to -0.11 (-60.71% YoY). Gross margin remained at 100%.
No analyst rating or price target changes available.
